Hemogenyx Pharmaceuticals Expands Clinical Trial to Include Pediatric Patients
The biotechnology company has filed an amendment to include children and adolescents with relapsed/refractory acute myeloid leukemia in its ongoing Phase I clinical trial for its CAR-T therapy HG-CT-1.